Long-Term Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B
Author Information
Author(s): Zhang Qin-Qin, An Xuan, Liu Ying-Hong, Li Shi-Ying, Zhong Qing, Wang Jing, Hu Huai-Dong, Zhang Da-Zhi, Ren Hong, Hu Peng
Primary Institution: Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China
Hypothesis
Can long-term nucleos(t)ide analogues therapy reduce the risk of long-term complications in adults with chronic hepatitis B?
Conclusion
Long-term nucleos(t)ide analogue therapy for adults with chronic hepatitis B prevents or delays the development of long-term complications.
Supporting Evidence
- Patients receiving nucleos(t)ide analogues had a 74% lower incidence of long-term complications compared to those who did not receive treatment.
- Drug-resistant patients still benefited from nucleos(t)ide analogue therapy, showing a significantly lower incidence of complications.
- Patients with pre-existing compensated cirrhosis had a higher risk of developing long-term complications compared to those without.
Takeaway
Taking antiviral medicine for a long time can help people with chronic hepatitis B avoid serious health problems later on.
Methodology
Meta-analysis of six studies comparing long-term nucleos(t)ide analogues therapy to no treatment.
Potential Biases
Potential bias due to the inclusion of non-randomized studies and varying patient selection criteria.
Limitations
The analysis included non-randomized studies and had varying follow-up durations.
Participant Demographics
Participants included adults with chronic hepatitis B, with varying ages and gender distributions across studies.
Statistical Information
P-Value
0.00001
Confidence Interval
0.15-0.47
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website